SFX by Ex Libris Inc.

Title:	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Source:	Nature [0028-0836] Do, R yr:2014

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Cholesterol Treatment Trialists' Ctt Collaborators, C. "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials." Lancet 380.9841 (2012): 581-590.
description	2.	Hamajima, N. "Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese ^\|^mdash; a cross-sectional data from the J-MICC Study." endocrine journal 59.7 (2012): 589-599.
description	3.	Fahed, Akl C. "The Lebanese allele at the LDLR in normocholesterolemic people merits reconsideration of genotype phenotype correlations in familial hypercholesterolemia." Endocrine 42.2 (2012): 445-8.
description	4.	Brown, Michael S., Michael S. "How LDL Receptors Influence Cholesterol and Atherosclerosis." Scientific American 251.5 (1984): 58-66.
description	5.	Dorfmeister, W. "Effects of Six APOA5 Variants, Identified in Patients With Severe Hypertriglyceridemia, on In Vitro Lipoprotein Lipase Activity and Receptor Binding." Arteriosclerosis, thrombosis, and vascular biology 28.10 (2008): 1866-71.
description	6.	Cholesterol Treatment Trialists' Ctt Collaboration, C. "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials." Lancet 376.9753 (2010): 1670-81.
description	7.	Baigent, C s. "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins." Lancet, The 366.9493 (2005): 1267-1278.
description	8.	Sattar, N. "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials." The Lancet 375.9716 (2010): 735-742.
description	9.	Trialists, Jordan T. "Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials." Lancet (London, England) 385.9976 (2015): 1397-1405.
description	10.	Heart Protection Study Collaborative Group, R. "Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial." Lancet 378.9808 (2011): 2013-2020.
description	11.	Matsunaga, A. "Strong Linkage Disequilibrium and Association of -1131T>C and c.553G>T Polymorphisms of the Apolipoprotein A5 Gene With Hypertriglyceridemia in a Japanese Population." Circulation Journal 71.5 (2007): 746-752.
description	12.	Bañares, Virginia G. "Preliminary spectrum of genetic variants in familial hypercholesterolemia in Argentina." Journal of clinical lipidology 11.2 (2017): 524-531.
description	13.	Huang, Y. "Functional importance of apolipoprotein A5 185G in the activation of lipoprotein lipase." Clinica chimica acta 413.1-2 (2012): 246-250.
description	14.	Yang, D. "Interactions between the apolipoprotein a1/c3/a5 haplotypes and alcohol consumption on serum lipid levels." Alcoholism: clinical and experimental research 37.2 (2013): 234-43.
description	15.	Fahed AC, Safa RM, Haddad FF, Bitar FF, Andary RR, Arabi MT, Azar ST, Nemer G;, Akl C. "Homozygous familial hypercholesterolemia in Lebanon: A genotype/phenotype correlation." Molecular genetics and metabolism 102.2 (2010): 181-188.
description	16.	Williams, Kevin J. "Some things just have to be done in vivo: GPIHBP1, caloric delivery, and the generation of remnant lipoproteins." Arteriosclerosis, thrombosis, and vascular biology (2009): 792-5.
description	17.	Holmkvist, J. "Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes." Diabetes 57.6 (2008): 1738-44.
description	18.	Cohen, Jonathan C C. "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease." The New England journal of medicine 354.12 (2006): 1264-72.
description	19.	Van Lenten, B J J. "Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures." The journal of clinical investigation 96.6 (1996): 2758-67.
description	20.	Brown, M S S. "Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man." Science 185.4145 (1974): 61-3.